John Vieceli Sells 15,112 Shares of Quantum-Si (NASDAQ:QSI) Stock

Quantum-Si Incorporated (NASDAQ:QSI) insider John Vieceli sold 15,112 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $0.90, for a total transaction of $13,600.80. Following the completion of the transaction, the insider owned 1,140,434 shares of the company’s stock, valued at approximately $1,026,390.60. The trade was a 1.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Quantum-Si Trading Up 3.6%

Shares of QSI opened at $0.86 on Friday. The business’s fifty day simple moving average is $0.99 and its two-hundred day simple moving average is $1.03. Quantum-Si Incorporated has a 12 month low of $0.69 and a 12 month high of $3.10. The company has a market cap of $186.69 million, a price-to-earnings ratio of -1.68 and a beta of 3.18.

Quantum-Si (NASDAQ:QSI) last posted its earnings results on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%.The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. As a group, research analysts forecast that Quantum-Si Incorporated will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of Quantum-Si by 15.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock valued at $131,000 after purchasing an additional 9,005 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Quantum-Si by 27.4% in the second quarter. The Manufacturers Life Insurance Company now owns 49,082 shares of the company’s stock worth $96,000 after buying an additional 10,564 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of Quantum-Si in the second quarter worth approximately $25,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Quantum-Si by 23.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock valued at $85,000 after buying an additional 13,546 shares during the period. Finally, Cerity Partners LLC purchased a new stake in Quantum-Si during the second quarter valued at approximately $29,000. 39.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on QSI. Weiss Ratings reissued a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group decreased their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a report on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $1.00.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.